Answers are grounded in this paper and cite their sources.
NASH)Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent form of liver disease associated with obesity, diabetes, and other metabolic diseases. 1NAFLD is characterized by hepatocyte lipid accumulation.Left untreated, this disease can progress to non-alcoholic steatohepatitis (NASH), typified by increased hepatocyte death, hepatocyte ballooning, inflammation, and fibrosis. 2,3The molecular basis of NAFLD/NASH development and progression is still poorly understood; thus, no effective treatments currently exist to combat this burgeoning health problem.Broadly, triglyceride (TG) metabolism in the liver involves at least four processes: (i) Liver TG uptake from very low-density lipoprotein (VLDL) remnants and chylomicrons within the plasma; (ii) Hepatic de novo lipid synthesis; (iii) Mitochondrial fatty acid betaoxidation-mediated TG and fatty acid turnover for energy generation; (iv) Excess TG storage within lipid droplets (LDs) or through delivery to other tissues in the form of VLDL in an apolipoprotein B100 (APOB100)-dependent process. 4,5Alteration of one or more of these processes may induce hepatic steatosis.To maintain hepatic lipid homeostasis, hepatocytes increase the formation of either LDs on the cytoplasmic face of the endoplasmic reticulum (ER) or VLDL on the luminal face of the ER, dependent on the ER-derived phospholipid coating of the growing neutral lipid cores. 6DL biogenesis and assembly take place within the lumen of the ER (Fig. 1).APOB100, which is synthesized within the rough ER, translocates to the ER lumen where it recruits
No takes yet. Share an insight, caveat, or question.
Ni et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: